Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
This study is an open-label, phase II study with a safety lead-in to assess the response rate of induction olaparib and stereotactic beam radiotherapy (SBRT) followed by combination olaparib/pembrolizumab in patients with metastatic gastric and GEJ cancers after at least one of therapy.
Epistemonikos ID: 4631a8661c2707c49ffcb23d8c28c94a04077389
First added on: May 13, 2024